Loading
The multikinase inhibitor lenvatinib shrank tumours in about one in six patients with progressing adenoid cystic carcinoma and stabilised most of the rest, making it one of the few active drugs for this slow-growing salivary cancer.
Single-arm phase 2 study of 32 patients with progressive recurrent or metastatic adenoid cystic carcinoma treated with lenvatinib 24 mg daily.
Partial response occurred in 15.6 percent and stable disease in 75 percent, with a median progression-free survival of 17.5 months; most patients required dose reductions for hypertension, fatigue and oral pain.
Lenvatinib (like axitinib) is a guideline option for progressing adenoid cystic carcinoma; responses are uncommon, so it is reserved for documented progression rather than indolent disease.